Journal
KIDNEY INTERNATIONAL
Volume 97, Issue 4, Pages 655-656Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2019.12.020
Keywords
-
Categories
Funding
- Australian National Health and Medical Research Council CJ Martin Overseas Biomedical Early Career Fellowship
Ask authors/readers for more resources
A dose escalation study of adipose-derived human mesenchymal stem cell (MSC) therapy was studied in 21 subjects. This dose escalation study confirmed no significant cellular toxicity, but it showed improvement in renal oxygenation and glomerular filtration rate. No significant renal toxicity from cell therapy was shown. A reduction in inflammatory markers including tumor necrosis factor-a, interferon-g, and neutrophil gelatinase-associated lipocalin was noted in subjects receiving MSC therapy. This study provides short-term safety and renal efficacy for MSC therapy and paves the way forward for future MSC-based interventions in renovascular disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available